Background/Aims: MicroRNAs (miRNAs) have been described to have important roles in primary immune thrombocytopenia (ITP). To gain additional understanding, we have now further evaluated the involvement of miRNAs in ITP. Methods: Microarray experiments were performed to examine the expression profiles of miRNAs and mRNAs in samples from subjects with newly diagnosed ITP (G1), chronic ITP (G2), and normal controls. The systematic Pipeline of Outlier MicroRNA Analysis framework was applied to identify key miRNAs expressed in the G1 and G2 samples. Quantitative PCR and receiver operator characteristic curves were used to confirm the performance of key miRNAs. Results: Compared with normal controls, 14 miRNAs (12 over-expressed and 2 under-expressed) and 7 over-expressed miRNAs were identified as key in G1 and G2 samples, respectively. miR-106b-5p, miR-200c-3p, and miR92a-3p exhibited significantly different expression profiles among the groups. In particular, miR-106b-5p and miR-200c-3p were expressed at higher levels in patients with ITP compared to the normal controls. Furthermore, these two miRNAs expressions were even higher in patients with chronic ITP. Conclusion: MiR-106b-5p and miR-200c-3p may represent valuable biomarkers of ITP, although further studies are needed to confirm and assess the value of these potential biomarkers at various stages of ITP.
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Introduction
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease that is primarily characterized by a reduction in numbers of platelets, skin and mucous membrane bleeding, and menorrhagia and internal bleeding. Consequently, ITP represents a severe and life threatening disease.
The pathogenesis of ITP remains incompletely understood, yet it appears to be highly multifactorial [1] [2] [3] . ITP involves isolated thrombocytopenia [4] as a result of anti-platelet antibody production by plasma cells that induce antibody-mediated platelet phagocytosis [5, 6] , T-cell mediated platelet destruction [7] , and/or impairment of megakaryocyte function [8] [9] [10] . In recent years, immune dysregulation due to ITP, especially cellular immune deficiency, has been an active area of research [11] . In patients with ITP, GPIIb-IIIa autoreactive CD4 + T cells, which facilitate the production of platelet autoantibodies by plasma cells, have been found [12] . T-cell mediated cytotoxicity is one mechanism by which platelet destruction is promoted, and this may occur during ITP in the absence of platelet autoantibodies [13] . Acute ITP (a hemorrhagic disease) most commonly affects children, while chronic ITP is most commonly diagnosed in adults. Currently, clinical therapy for ITP includes three stages of treatment. First line treatments include the administration of corticosteroids with or without intravenous IVIG and anti-D to inhibit the production of anti-platelet antibodies and platelet breakdown. Second line treatments include immunosuppressive agents such as anti-CD20 therapy with rituximab and splenectomy. Finally, third line treatments involve the stimulation of platelet production by megakaryocytes by Thrombopoietin-receptor agonists [1, 14] .
MicroRNAs (miRNAs) are 19-23-nucleotide single-stranded regulatory RNA molecules that lead to target gene degradation or inhibit gene translation following transcription via complete or incomplete complementary binding. MiRNAs participate in various biological processes and play critical roles in the development of various diseases, including cancer, cardiovascular disease, Alzheimer's disease, and immune system disorders [15, 16] . Abnormal miRNA expression has also been detected in patients with autoimmune diseases, such as systematic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis [17] [18] [19] . Recently, researchers have begun to pay attention to the important roles of miRNAs in ITP, and several groups have reported that dysregulated miRNAs may be critical regulatory molecules involved in the pathogenesis of this disease. A significant increase in miR-155 expression [20] and decreased expression of miR-130a [21] and miR-409-3p [22] were previously reported for patients with ITP compared with normal controls. In addition, Jernas et al [23] . identified 17 miRNAs that regulate immunological pathways in T cells in ITP. The differential expression of 44 miRNAs has also been documented in patients with ITP before and after treatment with Qishunbaolier (also called Xuebaowan or Shengxuekang) which is composed of 18 kinds of Chinese herbal medicines in a recipe that calls for: Dianthus superbus, safflower, gardenia, bezoar, Cornu Bubali, gamene, lacca, bear gall, saffron, Lithospermum, and Rubia [24] . Platelets that are anucleated express significant levels of RNA, including mRNAs, structural and catalytic RNAs, non-coding RNAs, and regulatory RNAs (e.g., miRNAs). Platelets can also translate mRNAs into proteins or their RNA can be transferred to target cells to regulate cellular functions [25] [26] [27] [28] . Currently, the functions of miRNAs that contribute to the pathogenesis and mechanism of ITP remain largely uncharacterized, and thus, much research is still needed.
In this study, we sought to identify miRNAs that exhibit significant changes in expression between newly diagnosed ITP and chronic stages of ITP and between each stage and normal controls. Therefore, we initially employed high-throughput microarray technology to measure the expression profiles of miRNAs and genes in peripheral blood cells samples from patients with newly diagnosed ITP, those with chronic ITP, and normal controls. Then, we used the systematic Pipeline of Outlier MicroRNA Analysis (POMA) framework [29, 30] to identify candidate key miRNAs in the two ITP stages based on the miRNA and messenger 
Materials and Methods
Subjects
Seventy patients with ITP, comprising 35 patients with newly diagnosed ITP (group 1 [G1]) and 35 patients with chronic ITP (group 2 [G2]), who were followed at the People's Liberation Army 100th Hospital and the First Affiliated Hospital of Soochow University between 2013 and 2015 were enrolled in this study. In addition, 35 healthy donors were enrolled as the normal control (N) group. Newly diagnosed ITP patients who did not receive any treatment and chronic ITP patients who had not received glucocorticoid or immunosuppressive agents for at least 3 months before sampling were included in our study. While primary ITP cases were included, secondary ITP cases were excluded. The primary ITP patients had no previous history of infection up to three months prior to being enrolled. Written informed consent was obtained from all participating individuals and the study procedure was approved by the ethics committees of the two hospitals involved.
Newly diagnosed and chronic ITP were defined according to the establishment of diagnoses ≤ 3 months and ≥ 12 months from the beginning of the study period, respectively, according to criteria reported in 2009 [4] . Platelet counts ranged from 2 × 10 9 /L to 30 × 10 9 /L for the newly diagnosed ITP patients and from 2 × 10 9 /L to 43 ×10 9 /L for the chronic ITP patients. A total of 67 adult patients were included in the study, as well as two children aged 13 and 17 years who were included in the newly diagnosed ITP group and one patient aged 17 years who was included in the chronic ITP group. Patients were classified as untreated if they had received no glucocorticoid or immunosuppressive agents for at least 3 months before sampling. Pregnant subjects and those with complications of diabetes, hypertension, cardiovascular disease, active infection, or autoimmune diseases other than ITP were excluded. Platelet autoantibodies were detected in ITP patients with a flow cytometric immunobead array [31] . Specificity of the antibodies, GPIIIa(SZ21), GPIIB(SZ22), GPIB(SZ2), and GPIX(SZ1), against human platelets were 91.4%, 88.5%, 91.4%, and 94.2%, respectively.
Peripheral blood mononuclear cell preparation and RNA extraction
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral venous blood, which was collected into EDTA-anticoagulated vacuum tubes, by Ficoll-Hypaque density gradient centrifugation (Ficoll Histopaque; Sigma, St. Louis, MO, USA). Total cellular RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions. RNA yield and purity were determined spectrophotometrically at 260/280 nm. polymerase chain reaction (RT-qPCR). miRNA expression profiling was conducted using RNA samples from three patients per group with the miRCURY LNA microarray (miRBase 18.0) system (Exiqon, Vedbaek, Denmark). RNA samples were labeled with the Exiqon miRCURY Hy3/Hy5 power labeling kit and hybridized on the miRCURY LNA Array [32] . Images were scanned with an Axon GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA), then imported into GenePix Pro 6.0 software (Axon) for grid alignment and data extraction. Replicated miRNAs were averaged and those with intensities ≥ 30 in all samples were chosen for calculation of the normalization factor. Expressed data were normalized using median normalization. miRNAs yielding results of p < 0.05 (t-test) and |Fold change| > 2 between two groups were selected as significant differentially expressed miRNAs (DE-miRNAs). mRNA expression profiles of the same nine samples were derived using the Human lncRNA microarray system (ver. 3.0; Arraystar Inc., MD, USA), which includes 26, 109 protein-coding mRNAs and 30, 586 long noncoding RNAs from the human genome. Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology) with minor modifications. Microarray hybridization and pre-processing analysis were performed by Kang Chen Bio-Tech, Shanghai, China. The mRNA intensity was normalized using quantile normalization, and the raw intensity was transformed to log 2 format. mRNAs showing significant differential expression between two groups (DE-mRNAs; p < 0.05, t test) were identified through |Fold change| > 2.
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNA was isolated from PBMCs using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. It was then used to synthesize complementary DNA using miRNA-specific primers and ProtoScript II reverse transcriptase (RT; NEBNext). qPCR was performed using an ABIPRISM7500 system (Applied Biosystems, Foster City, CA, USA). U6 small nuclear RNA was quantified as a control to normalize differences in total RNA level. All PCRs were repeated three times. The relative expression of the miRNAs was determined using the 2 −ΔΔCt method. The Wilcoxon and Kruskal-Wallis tests were used to determine the significance of expression differences between group pairs and among the three groups (two-tailed, p < 0.05), respectively. All statistical analyses and receiver-operating characteristic (ROC) curves were performed in R software [33] and the ROCR package [34] , respectively. Differential expression of miRNAs identified by POMA was assessed with qRT-PCR.
Bioinformatics analysis
In the POMA framework, the whole miRNA-mRNA network was constructed by integrating experimentvalidated and software-predicted miRNA regulations. Differentially expressed miRNAs and/or genes were then mapped to the whole network to infer specific miRNA-mRNA subnetworks [12, 20] . According to the framework, stage-specific miRNA-mRNA networks were built, and key miRNAs in the subnetworks were identified on the basis of significant differential expression of miRNAs and genes between each ITP group and the N group using improved POMA [29, 30] . We also constructed a G2' miRNA-mRNA network based on the identification of DE-miRNAs and DE-mRNAs between G2 and G1. POMA integrates expression profiles and miRNA-mRNA interactions to identify key miRNAs by exploring the substructure of the miRNA regulatory network. In the POMA, two miRNA network parameters (novel out-degree [NOD] and transcription factor percentage [TFP]) were proposed to identify key miRNAs in the stage-specific miRNA-mRNA networks. The NOD, defined as the number of genes targeted exclusively by a certain miRNA (also called unique target genes), was used to measure the independent regulatory power of individual miRNAs. The TFP of the miRNA target genes was used to measure miRNA function. miRNAs in the miRNA-mRNA network with significantly larger NOD and TFP values (p < 0.05, Wilcoxon test) were selected as key miRNAs in patients with newly diagnosed and chronic ITP. Network visualization was performed using Cytoscape software [35] .
Functional enrichment analysis of the predicted target genes of the miRNAs was performed in DAVID software [36] . Significance 
Results
Differential expression of miRNAs and mRNAs
To explore key miRNAs involved in different stages of ITP, we used microarray technology to measure the expression profiles of miRNAs and mRNAs in peripheral blood mononuclear cells (PBMCs) obtained from three subjects in each group. The differential expression profiles of the miRNAs and mRNAs detected were then examined and compared among the three groups. All of the differentially expressed genes that were detected are summarized in Table  2 and Fig. 2 . A comparison of the G2 group data and the N group data revealed the largest number of differentially expressed miRNAs (216 were up-regulated and 150 were downregulated) and mRNAs (696 were up-regulated and 1180 were down-regulated). In contrast, a comparison of the G1 data and the G2 data revealed the fewest number of differentially expressed miRNAs (55 were up-regulated and 45 were down-regulated) and mRNAs (112 were up-regulated and 515 were down-regulated).
Stage-specific miRNA-mRNA networks and key miRNAs in both stages of ITP The G1 network (Fig. 3) consisted of 63 miRNAs, 167 mRNAs, and 249 regulations. The G2 network (Fig. 4) consisted of 72 miRNAs, 253 mRNAs, and 418 regulations. The G2' network consisted of only 3 miRNAs, 2 target genes, and 3 regulations, and was therefore excluded from further analysis. All of the nodes in the networks represented miRNAs or mRNAs that were significantly differentially expressed.
When the NOD and TFP network parameters were applied, 14 key miRNAs were identified in the G1 network, with 12 up-regulated and 2 down-regulated, while all 7 key miRNAs in the G2 network were up-regulated (Table 3) . Three miRNAs (miR-106b-5p, miR-200c-3p, and miR-92a-3p) had significantly higher NOD and TFP values in both of the stage-specific networks that were examined. These results indicate that all three miRNAs exhibited strong independent regulatory power and regulated a greater number of transcription factors in both of the stage-specific networks. Moreover, these results suggest that these miRNAs play key roles in ITP pathogenesis and abnormal expression of them may have a strong and extensive influence on downstream targets. For example, there were autoimmune-related genes targeted by the key miRNAs that were identified, and these genes exhibited significant changes in expression between the G1 and G2 groups (IFNB1, CXCL2, TANK, and PTEN were identified in the G1/N group and CXCL11, CD69, and TANK were identified in the G2/N group). 
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Functional enrichment of targets of candidate key microRNAs
Target genes of key miRNAs in G1 and G2 were enriched significantly in biological process terms related to enzyme activities, including activation of caspase activity and regulation of caspase, peptidase, and endopeptidase activities (Fig. 5) . In G1, key miRNA targets were also enriched in terms related to vessel development; in G2, target genes were enriched terms related to transcription and apoptosis.
Among KEGG pathways, only the apoptosis pathway was enriched significantly by the targets of miRNAs in G1; no pathway in G2 showed significant enrichment, according to adjusted p values (Table 4) . Pathways with unadjusted p values < 0.05 are also listed in Table  4 ; according to this threshold, the apoptosis and neurotrophin-signaling pathways were enriched by the targets in the two stages. In addition, target genes of candidate miRNAs in G2 were enriched in the RIG-I-like receptor signaling pathway. All results indicated that the identified miRNAs play important and different roles in newly diagnosed and chronic ITP.
Verification of miRNA differential expression in patients with ITP
Results were consistent with those obtained by POMA for miR-106b-5p and miR200c-3p, which showed significantly differential expression between all group pairs ( Fig.  6A-C) . The expression of miR-92a-3p did not differ between G1 and the N group, but was significantly increased in G2 compared with G1 and the N group. The Kruskal-Wallis test revealed significant differences in the expression of these three miRNAs among the three groups (p<0.01). ROC curves for the three miRNAs are shown in (Fig. 6D-F) . The areas under the ROC curves (AUCs) were 0.63-0.92, indicating that the miRNAs can be used to effectively differentiate ITP stages. The largest AUC (0.92) was obtained for differential miR-106b-5p expression between G1 and the N group. Differences in the expression of miR-106b-5p and miR-200c-3p could distinguish G2 from the N group (both AUC = 0.88).
Discussion
An understanding of the pathogenesis and mechanisms of ITP is very important for the prevention, diagnosis, prognosis, and treatment of this disease. In this work, we employed POMA to identify key miRNAs expressed in samples obtained from ITP patients that were newly diagnosed (G1) versus managing a chronic ITP condition (G2). POMA is a framework that has been used to identify candidate miRNA biomarkers for diseases by integrating microarray profiling with experimental and predicted miRNA-mRNA interactions [29, 30] . There are two filter parameters, NOD and TFP, which were incorporated into the framework of POMA to measure the importance of miRNAs in a given network. They do this by accounting for the sub-structure topological properties and biological functions of elements in miRNAmRNA networks. POMA identified 14 miRNAs and 7 miRNAs with significantly higher NOD and TFP values in the G1 and G2 samples, respectively. Targets of these key miRNAs showed enrichment in enzyme activities related to GO processes (activation of caspase activity; regulation of caspase, peptidase, and endopeptidase activities) in both ITP stages. These activities, especially those related to caspase, have been reported to be associated with ITP [37, 38] . Decreased expression of TRAIL, caspase-8, and caspase-3 in megakaryocytes after culture in plasma from patients with ITP, consistent with the inhibition of megakaryocyte apoptosis and reduced production of platelets, has been reported [39] . Another study suggested that decreased caspase-8 and caspase-10 expression is related to the effects of thalidomide on mesenchymal stem cells, which may contribute to the pathogenesis of ITP [38] .
The observation that only a subset of patients with newly diagnosed ITP develop to chronic ITP is both interesting and important. In a prospective study, platelets, previous infections, and a FGR2B-232I/T genotype were found to predict the development of chronic ITP in patients that were newly diagnosed with ITP during childhood [32] . In contrast, patients who received IVIG had a significantly lower risk for developing chronic ITP [40] . The results of the present study demonstrate that significant differences exist between the miRNA expression profiles of newly diagnosed and chronic ITP patients, and these differences are consistent with the clinical manifestations and gene expression profiles previously characterized for newly diagnosed ITP patients versus chronic ITP patients.
In G1, targets of 14 key miRNAs were also enriched in the regulation of cell proliferation 
and vessel development; in G2, the target genes of 7 miRNAs were also enriched in transcription and apoptosis. One of the most important differences between these two ITP stages is related to cell proliferation. In this context, T and B lymphocytes and monocytes have drawn the attention of some researchers [41] [42] [43] . The dysregulation of proliferative T cells could lead to the failure of immune tolerance to self-platelet antigens, resulting in persistent autoantibody production by B cells [44] . Non-classical subsets of monocytes were found to be prominently elevated in patients with active ITP, contributing to the proliferation of platelet-reactive T cells and the production of interferon gamma [45] . Intermediate subsets of monocytes were also found to be increased, leading to the higher levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β, in negative correlation with platelet counts [42] . A recent publication showed that CD16+ monocytes could promote the development of Th1 
cells, but inhibited the proliferation of Tregs and IL-17(+) Th cells, resulting in the imbalance of Th subsets and further contributing to the pathogenesis of ITP [46] . Pathological vascular development is also thought to participate in the biological processes of many autoimmune diseases, such as ITP. The classical activation of platelet-mediated complements, such as C3, was observed in adhering and suspending active platelets, which may take part in vessel inflammation and thrombus formation [47, 48] . Both apoptosis and neurotrophin-signaling pathways were enriched as targets in both of the miRNA groups examined in this study. Apoptosis is important for normal development of the immune system, and emerging evidence suggests that apoptosis failure is involved in the pathogenesis of autoimmune diseases, including ITP [49] [50] [51] [52] . Most ITP megakaryocytes exhibit ultrastructural features of (para-) apoptosis, probably due to the action of factors present in the plasma of ITP patients. When bone marrow biopsies of ITP patients that were characterized by extensive apoptosis were examined by immunohistochemistry, a greater number of megakaryocytes containing activated caspase-3 were observed compared with normal megakaryocytes [53] . The role of neurotrophins in ITP has not been described, although neutrophins are thought to play roles in other autoimmune disorders, such as multiple sclerosis. Nerve growth factor, a neurotrophin, has been reported to be a therapeutic candidate in myelin repair [54] . The results of the present study indicate that the identified miRNAs play critical roles in ITP pathogenesis.
It was previously reported that miR-146a, miR-326, and miR-142-3p are expressed at lower levels in ITP patients, and expression of the latter tended to be inversely correlated with the frequencies of Th22 cells [55] . Moreover, it has been proposed that abnormal expression of miR-142-3p may contribute to the activation of self-reactive T cells in ITP patients [55] . In the present study, miR-142-3p expression was found to be abnormal and elevated. There are a few reasons why this difference in expression profile may have been observed. First, the previous cohort of patients were from various regions in northern China, while the patients in the present cohort were from the southeastern coastal areas of China. Second, our patients were either newly diagnosed or had chronic ITP. For both sets of patients, there was no history of medication for at least 3 months prior to enrollment. In contrast, the patients in the previous study had specimens possibly collected after treatment. Third, the number of cases in the present study were not sufficient to validate the results obtained. Therefore, follow-up studies with collections of larger quantities of specimens are needed.
When Bay et al. investigated plasma expression levels of 379 miRNAs in children affected by ITP, 7 miRNAs were found to be differentially expressed between acute patients, chronic patients, and normal individuals [56] . It is predicted that miR-302c-3p, miR-483-5p, miR-410, miR-544a, miR-302a-3p, miR-223-3p, and miR-597 target ITP-related genes, and these miRNAs have been found to be expressed at higher levels in ITP patients compared to normal subjects [56] . These results are inconsistent with the present results, and a possible reason for this may be the different specimens that were examined. Here, PBMCs were analyzed, while the study of Bay et al. examined plasma samples. In addition, there were a greater number of children included in the study by Bay et al. In contrast, our cohort mainly included adults.
In addition to studies of changes in miRNA expression profiles in ITP samples, abnormal expression of single miRNAs and interactions of target gene mRNAs have also been investigated. As a result, miR-155 [20] , miR-409-3p [22] , miR-130a [21] , and miR-125-5p [57] have gained attention. MiR-155 may contribute to the pathogenesis of ITP by regulating cytokine profiles via SOCS1 [20] , while reduced expression of miR409-3p has been detected in ITP patients and leads to up-regulation of IFNG [22] . MiR130A targets TGFB1 and IL-18 and reduced expression of miR130A has also been identified in ITP [21] . Finally, miR-125-5p may represent a potential biomarker by regulating the target gene, CXCL13 [57] . In the present study, changes in CXCL expression were observed, especially for CXCL11 and CXCL2. These results contribute to accumulating evidence that indicates that miRNAs are abnormally expressed in patients with ITP may contribute to the pathogenesis of ITP via the CXCL system. MiRNAs have also been reported to affect the function of megakaryocytes, which produce platelets. For example, miR-15 targets v-ets avian erythroblastosis virus E26 oncogene homolog 1 (ETS1), thereby enhancing megakaryopoiesis and the differentiation of megakaryocyte-erythroid progenitors into megakaryocytes [58] . In the present study, miR-15 expression was higher in the samples obtained from chronic ITP patients compared with the normal control samples, thereby indicating that miR-15 may play a role in the differentiation of megakaryocytes and their development to affect platelet production. Meanwhile, miR-27a has been shown to play a regulatory role in megakaryocytic differentiation by attenuating Runx1 expression [51] . During megakaryopoiesis, a feedback loop then mediates positive regulation of miR-27a expression by Runx1 [59] . In the present study, miR-27 was present at higher levels in the samples from newly diagnosed ITP patients compared with the normal control samples. These results suggest that in the early stages of ITP, interactions between miR-27 and RUNX1 contribute to the pathogenesis of ITP by mediating megakaryocyte differentiation.
In ITP patients, plasma levels of CXCL11 are increased, as well as gene expression of CXCL11 in PBMCs [60] . In this work, it is hypothesized that CXCL11 is an important chemoattractant for effector T cells involved in ITP, and indeed, in patients who responded to pulsed high-dose dexamethasone, CXCL11 expression was down-regulated [60] . CXCL2 is chemotactic for neutrophils and elevated expression of CXCL2 has also been associated with many inflammatory and autoimmune diseases [61, 62] . Atypical experimental autoimmune encephalitis correlates with preferential upregulation of CXCL2 in the brainstem, and it is driven by CXCR2-dependent recruitment of neutrophils [63] . In addition, CXCL2 can be induced by IL-17, a chemokine which plays an important role in ITP [64] . In the present study, miR-628-3p and its target gene, CXCL11, and miR-27a-3p and its target gene, CXCL2, were found to be abnormally expressed in the ITP samples examined. These two miRNAs may contribute to the pathogenesis of ITP through CXCL. TRAF associated NFκB activator (TANK) has been shown to have a key role in enabling regulation between canonical inhibitor of nuclear factor kappa-B kinases(IKKs) and IKK-related kinases, and this system is needed to limit the strength of TLR signaling and to ultimately prevent autoimmunity [65] . It has been demonstrated that TANK is not required for the production of IFNβ in response to viral infections. Rather, TANK limits MyD88-dependent TLR signaling to prevent the development of autoimmune nephritis. Moreover, TANK −/− mice overproduce IL-6 and other inflammatory mediators and develop autoimmune nephritis [66] . In the present study, abnormal expression of miR-30d-5p, miR-190b, and their common target gene, TANK, were detected in the ITP samples; thereby indicating that these two miRNAs may simultaneously regulate TLR signaling through TANK and participate in the pathogenesis of ITP.
PTEN regulates autoimmune arthritis by modulating the balance between Th17 and Treg. When PTEN is overexpressed, activation of T cells is reduced and the reciprocal differentiation of Th17 and Treg cells is modulated [67] . It has been proposed that induction of STAT3-modulatory activity of PTEN may represent a therapeutic target for rheumatoid arthritis [67] . The deletion of PTEN in myeloid cells was shown to inhibit the development of autoimmune arthritis by preventing the generation of a pathogenic Th17-type immune response [68] . In the present study, a potential role for miR-19b-3p in regulating PTEN and contributing to ITP pathogenesis was observed. Moreover, this role could lead to a Th17-mediated immune response imbalance.
Immune stimulation of molecules on the surface of lymphocytes is rapidly detected by CD69, and this leads to activation of ERK and maintenance of high expression levels of membrane-bound TGF-β1. Consequently, CD69 contributes to an inhibitory effect on CD4 + T cells [69] . CD69 has been associated with autoimmune diseases such as diabetes [70] , hepatitis [71] , and pancreatitis [72] . In the present study, both miR-92a-3p and miR-93-5p were found to be involved in the pathogenesis of ITP via a common target gene, CD69.
IFNβ is a type I interferon that is more potent than IFNα in inhibiting cell proliferation and inducing apoptosis and cell differentiation [73] , especially in autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Based on the presence of IFNβ in RA synovial membranes and its ability to reduce synoviocyte proliferation in vitro, it has been suggested that IFNβ is an anti-inflammatory mediator that has a protective role in RA [74] . In MS, apoptosis of autoreactive T cells is considered to be one of the antiinflammatory actions of IFNβ therapy [75] . The moderate efficacy observed for recombinant IFNβ treatments of MS patients further suggests that IFNβ has a therapeutic role rather than a role in the pathogenesis of MS [76] . In the present study, abnormal expression of miR26a-5p was observed and this miRNA may contribute to the pathogenesis of ITP via IFNβ to induce apoptosis and cell differentiation.
Validation of the identified miRNAs by RT-qPCR and ROC analysis showed significant differential expression among newly diagnosed ITP, chronic ITP, and normal control samples. Overexpression of miR-106b-5p and miR-200c-3p distinguished patients with ITP from normal controls, and was greater in chronic ITP than in newly diagnosed ITP. miR-106b-5p is thought to be involved in the development of a variety of diseases. In atherosclerotic diseases, it can inhibit the production of phosphatase and tensin homolog in vascular endothelial cells, blocking TNF-α-induced activation of caspase-3 and preventing endothelial cell apoptosis [77] . Serum miR-106b-5p has been shown to be a potential diagnostic biomarker for ischemic stroke [78] . miR-200c-3p, an important tumor-suppressive miRNA, can regulate cell-cycle mechanics and apoptosis in breast cancer and is a potential diagnostic biomarker distinguishing normal individuals from those with gastric cancer [79, 80] . In patients with high-grade serous ovarian carcinoma, miR-200c-3p is correlated with poor progression and may be involved in the pathological process of this disease [81] . The important roles of these miRNAs in ITP pathogenesis should be explored further in studies such as those employing qPCR in larger samples, or those investigating immune mechanisms in vitro and in vivo.
It should be noted that the majority of subjects in our study were adults, and cases of ITP have been observed to differ between children and adults. For example, ITP in children usually involves a self-limiting disease, and more than 80% of affected children have been fully restored. Moreover, only about 20% of children have persistent thrombocytopenia 1 year after their initial diagnosis of ITP. In contrast, chronic ITP is more commonly diagnosed in adolescents and adults [82] . Furthermore, almost two-thirds of the reported cases of children with ITP have a history of a viral infection, most commonly an upper respiratory tract infection, which occurred prior to the diagnosis of ITP. Meanwhile, in a minority of child ITP cases, the disease developed following vaccination with a live attenuated vaccine [83] . However, neither condition has been associated with ITP in adults.
This study has limitations to be noted. Firstly, the number of samples was not expansive. Hence, these results should be confirmed in an expanded study. Secondly, because the patients came predominantly from eastern China, the results may not be representative of patients from other geographic regions.
Conclusion
The present results indicate that abnormal expression of miRNAs, especially miR-106b-5p and miR-200c-3p, in patients with newly diagnosed ITP or chronic ITP may provide a basis for clinical diagnosis and treatment. However, these findings need to be further validated in larger cohorts. Functional experimental studies also need to be performed to further investigate the mechanistic details of the roles of these miRNAs in ITP.
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